Miguel Ángel Mina Hinestroza
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Miguel Ángel Mina Hinestroza has a total of 14 co-authors. Here are the top co-authors by number of shared publications:
- Rigoberto Gómez Gutiérrez
Hematology Service, IDC Hematooncólogos S.A, Cali, Colombia
2 shared publications Ana Maria Gómez
Hospital Universitario San Ignacio
1 shared publication- Antonio José Paredes Fernández
Universidad Libre
1 shared publication - Diana Cristina Henao-Carrillo
Pontificia Universidad Javeriana, Bogotá, Colombia; Hospital Universitario San Ignacio, Endocrinology Unit, Bogotá, Colombia
1 shared publication - Harol Cuello Bueno
Clínica Imbanaco
1 shared publication - José Darío Portillo-Miño
Departamento de Epidemiología y Salud Pública, Facultad de Ciencias de la Salud, Pontificia Universidad Javeriana. Cali, Colombia
1 shared publication
Latest Publications
- Open Access
- 20 July 2026
- Published by SAGE Publications in Clinical Medicine Insights: Endocrinology and Diabetes
- Vol. 19
Virtual vs. In-Person Training for MinMed™ 780G Initiation: Comparable Effectiveness and Safety in Adults with Type 1 Diabetes
Background: A knowledge gap persists regarding whether virtual training differs from in-person training in terms of metabolic control and clinical safety among adults with type 1 diabetes mellitus (T1D) initiating the MiniMed™ 780G advanced hybrid closed-loop (AHCL) system. Methods: Observational study comparing two retrospective cohorts of adult patients with type 1 diabetes mellitus (T1DM) treated with the Medtronic MiniMed™780G hybrid closed-loop insulin automation system: one cohort trained in-person and a second cohort trained virtually at the Hospital Universitario San Ignacio, Bogotá (Colombia). Metabolic control and safety parameters were evaluated 12 weeks after training initiation. A logistic regression model was developed to identify factors associated with meeting glycemic target (Time in range 70–180 mg/dL ≥ 70%) at 12 weeks. Results: 191 patients were analyzed; (49.7% virtual 50.3% in-person training). After 12 weeks, no statistically significant differences were observed in TIR between the cohorts (75% vs. 77.5%, p = 0.51). Severe hypoglycemia (<54 mg/dL) decreased significantly in both groups (p<0.02), without differences between cohorts. The type of training was not significantly associated with achieving the goals of TIR (adjusted OR 0.78; 95% CI:0.16–3.82; p=0.76). Younger age (<45 years) was independently associated with improved metabolic control (adjusted OR 0.08; 95% CI:0.01–0.75; p=0.02). Higher socioeconomic status showed a trend toward better outcomes (adjusted OR 35.04; 95% CI:0.94–1260.6; p=0.05). Conclusions: Both virtual and in-person training are effective and safe strategies for initiating the MiniMed™ 780G AHCL system in adults with T1D, with no significant differences between training modalities.
- 20 July 2026
- Published by SAGE Publications in Clinical Medicine Insights: Endocrinology and Diabetes
- Vol. 19
Open AccessVirtual vs. In-Person Training for MinMed™ 780G Initiation: Comparable Effectiveness and Safety in Adults with Type 1 Diabetes
Background: A knowledge gap persists regarding whether virtual training differs from in-person training in terms of metabolic control and clinical safety among adults with type 1 diabetes mellitus (T1D) initiating the MiniMed™ 780G advanced hybrid closed-loop (AHCL) system. Methods: Observational study comparing two retrospective cohorts of adult patients with type 1 diabetes mellitus (T1DM) treated with the Medtronic MiniMed™780G hybrid closed-loop insulin automation system: one cohort trained in-person and a second cohort trained virtually at the Hospital Universitario San Ignacio, Bogotá (Colombia). Metabolic control and safety parameters were evaluated 12 weeks after training initiation. A logistic regression model was developed to identify factors associated with meeting glycemic target (Time in range 70–180 mg/dL ≥ 70%) at 12 weeks. Results: 191 patients were analyzed; (49.7% virtual 50.3% in-person training). After 12 weeks, no statistically significant differences were observed in TIR between the cohorts (75% vs. 77.5%, p = 0.51). Severe hypoglycemia (<54 mg/dL) decreased significantly in both groups (p<0.02), without differences between cohorts. The type of training was not significantly associated with achieving the goals of TIR (adjusted OR 0.78; 95% CI:0.16–3.82; p=0.76). Younger age (<45 years) was independently associated with improved metabolic control (adjusted OR 0.08; 95% CI:0.01–0.75; p=0.02). Higher socioeconomic status showed a trend toward better outcomes (adjusted OR 35.04; 95% CI:0.94–1260.6; p=0.05). Conclusions: Both virtual and in-person training are effective and safe strategies for initiating the MiniMed™ 780G AHCL system in adults with T1D, with no significant differences between training modalities.
- Open Access
- 20 February 2023
- Published by Asociacion Colombiana de Hematologia y Oncologia in Revista Colombiana de Hematología y Oncología
- Vol. 9 (2) , 138-148
Hemangioendotelioma cardiaco primario recurrente: reporte de caso y revisión de la literatura
Epithelioid hemangioendothelioma (EHE) is a malignant tumor possibly of vascular origin. Its usual location is the soft tissues, mediastinum, central nervous system, pleura, lungs, liver and bone. However, its appearance in the heart is extremely rare. We present the case of a 67-year-old male patient who consulted for progressive dyspnea, edema of the lower limbs and painful congestive hepatomegaly. Primary cardiac HEE is diagnosed by biopsy. Subsequently, tumor recurrence was documented, which is why the Tumor Board, which decided to start chemotherapy (Paclitaxel plus liposomal Doxorubicin for 6 cycles), evaluated him. The patient continues to be monitored by Oncology with evidence of stable disease. Primary cardiac HEE is a very rare tumor. Paclitaxel plus doxorubicin treatment is a chemotherapy regimen that may be considered in the management of advanced or recurrent primary cardiac HEE after cardiac surgery.
- 20 February 2023
- Published by Asociacion Colombiana de Hematologia y Oncologia in Revista Colombiana de Hematología y Oncología
- Vol. 9 (2) , 138-148
Open AccessHemangioendotelioma cardiaco primario recurrente: reporte de caso y revisión de la literatura
Epithelioid hemangioendothelioma (EHE) is a malignant tumor possibly of vascular origin. Its usual location is the soft tissues, mediastinum, central nervous system, pleura, lungs, liver and bone. However, its appearance in the heart is extremely rare. We present the case of a 67-year-old male patient who consulted for progressive dyspnea, edema of the lower limbs and painful congestive hepatomegaly. Primary cardiac HEE is diagnosed by biopsy. Subsequently, tumor recurrence was documented, which is why the Tumor Board, which decided to start chemotherapy (Paclitaxel plus liposomal Doxorubicin for 6 cycles), evaluated him. The patient continues to be monitored by Oncology with evidence of stable disease. Primary cardiac HEE is a very rare tumor. Paclitaxel plus doxorubicin treatment is a chemotherapy regimen that may be considered in the management of advanced or recurrent primary cardiac HEE after cardiac surgery.
- Open Access
- 1 November 2022
- Published by Asociacion Colombiana de Hematologia y Oncologia in Revista Colombiana de Hematología y Oncología
- Vol. 9 (1) , 37-46
La enfermedad de Kikuchi-Fujimoto: una gran imitadora. A propósito de un caso
Kikuchi-Fujimoto disease (KFD) is a great mimic. Its clinical presentation resembles infectious entities, as well as reumatological diseases, lymphoproliferative disorders, or metastatic lesions. It is a benign, rare, self-limited entity of unknown etiology. It generally affects the cervical lymph nodes, and its symptoms are varied. The following is the case of a previously healthy 29-year-old man with generalized lymphadenopathy associated with significant unintended weight loss, intermittent high fever, nocturnal sweating, and general malaise. Fluorine-18-labeled deoxyglucose positron emission tomography (PET / CT 18F-FDG) revealed multiple nodes with intense metabolic activity suggestive of malignancy, infectious entities, or autoimmune diseases, which were ruled out. Histopathological diagnosis confirmed necrotizing histiocytic lymphadenitis, compatible with KFD, a rare and underdiagnosed disease, where early recognition could avoid unnecessary diagnostic or therapeutic interventions.
- 1 November 2022
- Published by Asociacion Colombiana de Hematologia y Oncologia in Revista Colombiana de Hematología y Oncología
- Vol. 9 (1) , 37-46
Open AccessLa enfermedad de Kikuchi-Fujimoto: una gran imitadora. A propósito de un caso
Kikuchi-Fujimoto disease (KFD) is a great mimic. Its clinical presentation resembles infectious entities, as well as reumatological diseases, lymphoproliferative disorders, or metastatic lesions. It is a benign, rare, self-limited entity of unknown etiology. It generally affects the cervical lymph nodes, and its symptoms are varied. The following is the case of a previously healthy 29-year-old man with generalized lymphadenopathy associated with significant unintended weight loss, intermittent high fever, nocturnal sweating, and general malaise. Fluorine-18-labeled deoxyglucose positron emission tomography (PET / CT 18F-FDG) revealed multiple nodes with intense metabolic activity suggestive of malignancy, infectious entities, or autoimmune diseases, which were ruled out. Histopathological diagnosis confirmed necrotizing histiocytic lymphadenitis, compatible with KFD, a rare and underdiagnosed disease, where early recognition could avoid unnecessary diagnostic or therapeutic interventions.